Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q8041843> ?p ?o }
Showing triples 1 to 11 of
11
with 100 triples per page.
- Q8041843 subject Q7170959.
- Q8041843 subject Q8788410.
- Q8041843 abstract "XEN-D0101 is a drug that was developed to treat atrial fibrillation. Xention, a biopharmaceutical company based in Cambridge, United Kingdom, created XEN-D0101 along with other ion channel-modulating drugs. XEN-D0101 is a selective antagonist of the voltage-gated potassium channel Kv1.5. Atrial fibrillation is the main focus of Xention’s drug development, as it is the most common cardiac arrhythmia (irregular heart beat) seen in patients.".
- Q8041843 wikiPageWikiLink Q11269508.
- Q8041843 wikiPageWikiLink Q41861.
- Q8041843 wikiPageWikiLink Q7170959.
- Q8041843 wikiPageWikiLink Q815819.
- Q8041843 wikiPageWikiLink Q844935.
- Q8041843 wikiPageWikiLink Q8788410.
- Q8041843 comment "XEN-D0101 is a drug that was developed to treat atrial fibrillation. Xention, a biopharmaceutical company based in Cambridge, United Kingdom, created XEN-D0101 along with other ion channel-modulating drugs. XEN-D0101 is a selective antagonist of the voltage-gated potassium channel Kv1.5. Atrial fibrillation is the main focus of Xention’s drug development, as it is the most common cardiac arrhythmia (irregular heart beat) seen in patients.".
- Q8041843 label "XEN-D0101".